$LEGN earnings report

Legend Biotech reports Q3 2026 net income of $51.7 million versus a net loss a year earlier, as CARVYKTI net trade sales rose 36% to approximately $710 million. AlphAI read Legend Biotech's Q3 FY2026 filing as solid. 2 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readLEGN · Q3 2026 · ended 2026-09-30

Legend Biotech reports Q3 2026 net income of $51.7 million versus a net loss a year earlier, as CARVYKTI net trade sales rose 36% to approximately $710 million

✓Solid quarter

Q3 2026 shows operating income of $46.8 million, net income of $51.7 million and adjusted net income of $55.6 million, against losses in Q3 2025. Collaboration revenue rose to $353.2 million and CARVYKTI net trade sales grew 36%. Cash and time deposits fell to approximately $853 million and operating cash flow was negative in both the quarter and the nine months. No guidance was provided to compare against.

Revenue
$360M
Collaboration revenue (Janssen Agreement)
$353M
+$91.4 million y/y
EPS · non-GAAP
$0.14

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
CARVYKTI net trade sales, Q3 2026otherapproximately $710 million–36%
Collaboration revenue, Q3 2026GAAP$353.2M–+$91.4 million
License and other revenue, Q3 2026GAAP$6.3M–-$4.3 million
Total revenue, Q3 2026GAAP$359.5M––
Cost of collaboration revenue, Q3 2026GAAP$147M–+$33.8 million
Cost of license and other revenue, Q3 2026GAAP$600K––
Research and development expenses, Q3 2026GAAP$95.3M–-$17.9 million
Administrative expenses, Q3 2026GAAP$14.8M–-$19.9 million
Selling and distribution expenses, Q3 2026GAAP$55M–+$2.5 million
Operating income (loss), Q3 2026GAAP$46.8M–+$90.1 million
Finance costs, Q3 2026GAAP−$3.9M––
Finance income, Q3 2026GAAP$8.3M––
Other (expense) income, net, Q3 2026GAAP−$1.8M––
Income (loss) before tax, Q3 2026GAAP$49.4M––
Income tax benefit (expense), Q3 2026GAAP$2.3M––
Net income (loss), Q3 2026GAAP$51.7M–+$91.3 million
Basic EPS, Q3 2026GAAP$0.13––
Diluted EPS, Q3 2026GAAP$0.13––
Adjusted net income (loss), Q3 2026non-GAAP$55.6M–+$74.3 million
ANI per share, basic, Q3 2026non-GAAP$0.14––
ANI per share, diluted, Q3 2026non-GAAP$0.14––
Cash flows (used in) provided by operating activities, Q3 2026GAAP−$35.9M––
Collaboration revenue, nine months ended September 30, 2026GAAP$977.7M––
License and other revenue, nine months ended September 30, 2026GAAP$74.4M––
Total revenue, nine months ended September 30, 2026GAAP$1.05B––
Cost of collaboration revenue, nine months ended September 30, 2026GAAP−$458.4M––
Cost of license and other revenue, nine months ended September 30, 2026GAAP−$2.5M––
Research and development expenses, nine months ended September 30, 2026GAAP−$277M––
Administrative expenses, nine months ended September 30, 2026GAAP−$87.8M––
Selling and distribution expenses, nine months ended September 30, 2026GAAP−$168.5M––
Other operating expenses, nine months ended September 30, 2026GAAP−$3.2M––
Operating income (loss), nine months ended September 30, 2026GAAP$54.7M––
Finance costs, nine months ended September 30, 2026GAAP−$15.2M––
Finance income, nine months ended September 30, 2026GAAP$21.2M––
Other (expense) income, net, nine months ended September 30, 2026GAAP−$8.9M––
Income (loss) before tax, nine months ended September 30, 2026GAAP$51.8M––
Income tax (expense) benefit, nine months ended September 30, 2026GAAP−$21.2M––
Net income (loss), nine months ended September 30, 2026GAAP$30.6M––
Basic EPS, nine months ended September 30, 2026GAAP$0.08––
Diluted EPS, nine months ended September 30, 2026GAAP$0.08––
Adjusted net income (loss), nine months ended September 30, 2026non-GAAP$108.4M––
ANI per share, basic, nine months ended September 30, 2026non-GAAP$0.29––
ANI per share, diluted, nine months ended September 30, 2026non-GAAP$0.28––
Cash flows (used in) provided by operating activities, nine months ended September 30, 2026GAAP−$141.9M––
Cash and cash equivalents, and time deposits, September 30, 2026otherapproximately $853 million––

Segments

SegmentRevenueq/qy/y
Collaboration revenue (Janssen Agreement)Company explanation: increase due to higher revenue generated from sales of CARVYKTI in connection with the Janssen collaboration and license agreement. Cost of collaboration revenue rose $33.8 million, which the company attributes to Legend Biotech's share of the cost of sales in connection with CARVYKTI sales under the Janssen Agreement.$353.2M–+$91.4 million
License and other revenue (Novartis License Agreement)Company explanation: decrease primarily attributable to revenue recognized under the Novartis License Agreement for LB2102 and other DLL-3 targeting CAR-T therapies, which is recognized over time in connection with the Phase 1 clinical trial for LB2102.$6.3M–-$4.3 million
CARVYKTI net trade sales (total, J&J reported)Company states CARVYKTI net trade sales increased 36% versus Q3 2025 to approximately $710 million. CARVYKTI is available across 373 treatment sites in 20 global markets.approximately $710 million–36%
CARVYKTI United States net trade sales (J&J reported, 100%)Revenue per the J&J Q3 2026 earnings release, as reconciled in the filing. Growth figure stated by the company for U.S. net trade sales.$472M–19% (U.S. net trade sales growth)
CARVYKTI ex-U.S. net trade sales (J&J reported, 100%)Revenue per the J&J Q3 2026 earnings release, as reconciled in the filing. Reconciliation shows an F/X variance of $2 million for ROW on Legend's share.$238M–86% (ex-U.S. net trade sales growth)
CARVYKTI United States, Legend reported (50% share)Legend's 50% share of U.S. revenue as printed in the CARVYKTI revenue reconciliation, rounded in the filing.$236M––
CARVYKTI rest of world, Legend reported (50% share)Legend reported ROW revenue as printed in the CARVYKTI revenue reconciliation, rounded in the filing. The reconciliation shows a $2 million F/X variance for ROW.$117M––

Capital returns

  • No share repurchase or dividend figures are reported in this filing.

What drove it

  • Company explanation: operating income improvement was primarily due to higher gross profit from CARVYKTI, as well as lower research and development expenses and lower administrative expenses.
  • Company explanation: R&D decrease was primarily driven by lower expenditures in the cilta-cel clinical program as the patient dosing phases of major trials substantially concluded, partially offset by increased R&D activities related to in vivo CAR-T programs.
  • Company explanation: administrative expense decrease was primarily driven by lower share-based compensation expense associated with the forfeiture of certain unvested equity awards and the resulting reversal of previously recognized compensation expense, partially offset by higher professional fees.
  • Company explanation: selling and distribution increase was primarily due to higher commercial costs, including sales force expansion and Janssen-related marketing and market access activities.
  • Company explanation: net income improvement was primarily driven by improved operating income.
  • Company explanation: adjusted net income improvement was mainly driven by higher net income, partially offset by a lower share-based compensation adjustment.
  • Five-year CARTITUDE-2 Cohort A data: median PFS of 60.5 months, median overall survival not reached, and 69.2% of patients alive at five years (n=20, median follow-up 60.7 months).

Concerns

  • Operating cash flow was negative at $(35.9) million in Q3 2026 and $(141.9) million for the nine months ended September 30, 2026.
  • Cash and cash equivalents fell to $460.7 million from $901.9 million at December 31, 2025, and the quarter's net decrease in cash was $(212.2) million.
  • Collaboration interest-bearing advanced funding decreased to $44.1 million from $319.1 million at December 31, 2025, while time deposits rose to $391.8 million from $46.7 million.
  • License and other revenue declined $4.3 million year over year, which the company attributes to revenue recognition under the Novartis License Agreement.
  • The company's reported Q3 2026 administrative expense decrease reflects a reversal of previously recognized share-based compensation, which the company identifies as a driver.
  • Other (expense) income, net was $(8.9) million for the nine months ended September 30, 2026, and income tax expense for the nine months was $(21.2) million.

What to watch

  • Whether operating cash flow turns positive, given $(35.9) million in Q3 2026 and $(141.9) million for the nine months.
  • Trajectory of cash, cash equivalents and time deposits (approximately $853 million at September 30, 2026) and the company's stated ability to fund operations beyond 2026, referenced in its forward-looking statements.
  • CARVYKTI net trade sales growth outside the U.S., reported at 86%, and in the U.S., reported at 19%, against the NCCN Guideline changes cited by the company.
  • Cost of collaboration revenue trends as Legend's share of CARVYKTI cost of sales rises with collaboration revenue.
  • Progress of the LB2501 Phase I/II trial in the U.S. following the FDA IND clearance, and the Novartis LB2102 Phase 1 trial that drives license revenue.
  • Share-based compensation swings, which the company identifies as affecting administrative expense and adjusted net income in the quarter.

Balance sheet and cash flow

  • Cash and cash equivalents: $460.7 million at September 30, 2026, compared with $901.9 million at December 31, 2025.
  • Time deposits: $391.8 million at September 30, 2026, compared with $46.7 million at December 31, 2025.
  • Cash and cash equivalents, and time deposits: approximately $853 million as of September 30, 2026 (company statement).
  • Total assets: $1,681.4 million at September 30, 2026, compared with $1,733.7 million at December 31, 2025.
  • Collaboration interest-bearing advanced funding (current liability): $44.1 million at September 30, 2026, compared with $319.1 million at December 31, 2025.
  • Total liabilities: $408.7 million at September 30, 2026, compared with $731.6 million at December 31, 2025.
  • Total equity: $1,272.7 million at September 30, 2026, compared with $1,002.1 million at December 31, 2025.
  • Cash flows used in investing activities: $(124.9) million in Q3 2026 versus $(20.0) million in Q3 2025; $(412.9) million in the nine months ended September 30, 2026 versus $71.1 million in the nine months ended September 30, 2025.
  • Cash flows (used in) provided by financing activities: $(50.7) million in Q3 2026 versus $0.7 million in Q3 2025; $115.8 million in the nine months ended September 30, 2026 versus $0.4 million in the nine months ended September 30, 2025.
  • Net (decrease) increase in cash and cash equivalents: $(212.2) million in Q3 2026 versus $12.4 million in Q3 2025; $(441.2) million in the nine months ended September 30, 2026 versus $(7.8) million in the nine months ended September 30, 2025.
  • Cash and cash equivalents at end of period: $460.7 million at September 30, 2026 versus $278.9 million at September 30, 2025.

Analysis

Legend Biotech reported Q3 2026 total revenue of $359.5 million, against $272.4 million in Q3 2025. Collaboration revenue from the Janssen Agreement reached $353.2 million, up $91.4 million, and the company ties this to higher revenue from CARVYKTI sales. CARVYKTI net trade sales were approximately $710 million, up 36% year over year, with U.S. net trade sales up 19% and ex-U.S. net trade sales up 86%. The J&J-reported split shows $472 million in the U.S. and $238 million ex-U.S. on a 100% basis, while Legend's reported share was $236 million in the U.S. and $117 million in rest of world. License and other revenue was $6.3 million, down $4.3 million, which the company attributes to the Novartis License Agreement recognition over time for LB2102.

The cost base moved in two directions. Cost of collaboration revenue rose to $147.0 million from $113.2 million, which the company attributes to Legend's share of CARVYKTI cost of sales. R&D fell to $95.3 million from $113.2 million, and the company attributes this to lower cilta-cel clinical program spending as major trial dosing substantially concluded, partly offset by in vivo CAR-T work. Administrative expenses fell to $14.8 million from $34.7 million, which the company attributes mainly to a reversal of previously recognized share-based compensation. Selling and distribution rose to $55.0 million from $52.5 million. Operating income was $46.8 million, against an operating loss of $43.3 million a year earlier, and net income was $51.7 million, against a net loss of $39.6 million. Diluted EPS was $0.13 against $(0.11). Adjusted net income was $55.6 million, a non-GAAP measure, against $(18.7) million.

For the nine months ended September 30, 2026, total revenue was $1,052.1 million against $722.5 million, operating income was $54.7 million against $(116.9) million, and net income was $30.6 million against $(266.0) million. Other (expense) income, net was $(8.9) million for the nine months, against $(162.3) million, and the prior-year nine-month period included a large unrealized foreign exchange loss in the adjusted reconciliation.

Cash flow and the balance sheet show a different picture. Operating cash flow was $(35.9) million in Q3 2026 and $(141.9) million for the nine months. Cash and cash equivalents fell to $460.7 million from $901.9 million at December 31, 2025, while time deposits rose to $391.8 million from $46.7 million. The company states cash and time deposits of approximately $853 million. Collaboration interest-bearing advanced funding fell to $44.1 million from $319.1 million, and total liabilities fell to $408.7 million from $731.6 million. Total equity rose to $1,272.7 million from $1,002.1 million. No capital return figures are reported.

The clinical and regulatory items in the release, including five-year CARTITUDE-2 Cohort A data, the updated NCCN Guidelines and the FDA IND clearance for LB2501, are reported as company announcements without quantified financial effect.

Management, verbatim

We remain focused on disciplined execution, expanding access to CARVYKTI worldwide, advancing our innovative pipeline, and delivering sustained profitability.

Ingrid Zhang, Chief Executive Officer, Legend Biotech

Together, the promising early line data and updated NCCN guidelines preferring CAR-T ahead of other BCMA-directed therapies well positions CARVYKTI to potentially gain market share in the second- and third-line setting.

Ingrid Zhang, Chief Executive Officer, Legend Biotech

Not in the filing

stated, not guessed
  • Prior-year Q3 2025 figure for CARVYKTI net trade sales is not printed; only the 36% change is stated.
  • Year-over-year percentage change for total revenue is not printed.
  • Year-over-year change figures for cost of license and other revenue, EPS, finance costs, finance income, other (expense) income, income tax, and nine-month line items are not printed.
  • Prior-year figure for cash and cash equivalents and time deposits at September 30, 2025 is not printed in the balance sheet; the balance sheet compares to December 31, 2025.
  • Prior-quarter (Q2 2026) figures are not provided, so all quarter-over-quarter fields are null.
  • Prior-year figure for U.S. and ex-U.S. CARVYKTI net trade sales in dollars is not printed; only growth percentages are stated.
  • No capital return data (share repurchases or dividends) is reported.
  • Consensus estimates and share price reaction are not in the documents.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Q2 FY2026

AlphAI · Earnings readLEGN · Q2 2026 · ended June 30, 2026

CARVYKTI net trade sales increased 50% versus second quarter of 2025 to approximately $657 million as Legend Biotech reported IFRS net income of $33.2 million and adjusted net income of $63.1 million.

✓Strong quarter

CARVYKTI growth, higher collaboration and license revenue, and an operating-income and net-income turnaround supported the quarter, while the company also raised approximately $212 million and reported approximately $965 million of cash and time deposits.

Revenue
$388M
CARVYKTI net trade sales
approximately $657 million
50% y/y
EPS · non-GAAP
$0.16

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Collaboration revenueother$326.1M––
License and other revenueother$61.4M––
Total revenueother$387.5M––
Cost of collaboration revenueother−$136M––
Cost of license and other revenueother−$1.4M––
Research and development expensesother−$96M––
Administrative expensesother−$33M––
Selling and distribution expensesother−$63.4M––
Operating income (loss)other$57.7M––
Finance costsother−$5.8M––
Finance incomeother$5.6M––
Other expense, netother−$2M––
Income (loss) before taxother$55.5M––
Income tax expenseother−$22.3M––
Net income (loss)other$33.2M––
Basic earnings (loss) per shareother$0.09––
Diluted earnings (loss) per shareother$0.09––
Adjusted net income (loss)non-GAAP$63.1M––
Adjusted net income per share, basicnon-GAAP$0.17––
Adjusted net income per share, dilutednon-GAAP$0.16––
Cash flows used in operating activitiesother−$20.9M––
Cash flows used in investing activitiesother−$120M––
Cash flows provided by financing activitiesother$167.7M––
Cash and cash equivalents at end of periodother$672.9M––

Segments

SegmentRevenueq/qy/y
CARVYKTI net trade salesU.S. net trade sales growth of 32% and ex-U.S. net trade sales growth of 128% year-over-year.approximately $657 million–50%
Collaboration revenueIncrease in revenue generated from sales of CARVYKTI in connection with the Janssen collaboration and license agreement.$326.1M––
License and other revenueDriven by milestones of $56.0 million achieved under the Janssen Agreement, partly offset by no related party license revenue and lower revenue under the Novartis License Agreement.$61.4M––

2026 outlook

  • NoteLegend Biotech believes cash and cash equivalents and time deposits will provide financial runway beyond 2026.
  • NoteLegend Biotech believes it will achieve a company-wide profit in 2026. Company-wide profit is defined as Adjusted Net Income.

What drove it

  • CARVYKTI net trade sales increased 50% versus second quarter of 2025 to approximately $657 million.
  • Legend launched CARVYKTI in Ireland, bringing availability to 348 global sites and 19 global markets.
  • Operating income improvement was primarily due to higher gross profit from CARVYKTI and higher license and other revenue.
  • Research and development expense decreased primarily because patient dosing phases of major cilta-cel trials substantially concluded, partly offset by higher pipeline-related research and development activities.
  • Selling and distribution expense increased primarily because of sales force expansion and Janssen-related marketing and market access activities.
  • LB2501 reported 100% ORR (6/6) and 83.3% CR (5/6) at the higher dose level (DL2) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Concerns

  • Income tax expense was $22.3 million, and the company continues to negotiate an advance pricing agreement with the Chinese Tax Authority.
  • Legend stated that the final outcome with a tax authority may result in a tax liability materially different from that reflected in the consolidated financial statements.
  • Cash flows used in operating activities were $(20.9) million and cash flows used in investing activities were $(120.0) million for the three months ended June 30, 2026.
  • Selling and distribution expenses increased to $(63.4) million from $(48.1) million.
  • LB2102 reported an ORR of 28.6% and a DCR of 78.6% at higher dose levels in heavily pretreated patients.

What to watch

  • Execution of CARVYKTI expansion across 348 global sites and 19 global markets.
  • Whether higher CARVYKTI sales continue to increase collaboration revenue and gross profit.
  • Progress toward company-wide profit in 2026, defined as Adjusted Net Income.
  • Resolution of the advance pricing agreement with the Chinese Tax Authority.
  • Further clinical data for LB2501 and LB2102, including the reproducibility and durability of favorable initial results.

Balance sheet and cash flow

  • Cash and cash equivalents, and time deposits were approximately $965 million as of June 30, 2026.
  • Cash and cash equivalents were $672.9 million as of June 30, 2026.
  • Time deposits were $291.7 million as of June 30, 2026.
  • Collaboration interest-bearing advanced funding was $156.4 million as of June 30, 2026.
  • Total liabilities were $521.3 million as of June 30, 2026.
  • Total equity was $1,229.6 million as of June 30, 2026.
  • Closed a public offering of 7,700,000 American Depositary Shares with net proceeds of approximately $212 million, after deducting underwriting discounts and commissions and estimated offering expenses.
  • Cash flows used in operating activities were $(20.9) million for the three months ended June 30, 2026.
  • Cash flows used in investing activities were $(120.0) million for the three months ended June 30, 2026.
  • Cash flows provided by financing activities were $167.7 million for the three months ended June 30, 2026.

Analysis

Legend reported a materially improved Q2 2026 under IFRS. Total revenue was $387.5 million, comprising $326.1 million of collaboration revenue and $61.4 million of license and other revenue. CARVYKTI net trade sales increased 50% versus the second quarter of 2025 to approximately $657 million. U.S. net trade sales growth was 32%, while ex-U.S. growth was 128%, and the Ireland launch extended availability to 348 global sites and 19 global markets.

The revenue increase translated into operating income of $57.7 million, compared with an operating loss of $(21.9) million. Cost of collaboration revenue increased to $(136.0) million as CARVYKTI-related cost of sales increased, while selling and distribution expenses rose to $(63.4) million with sales force expansion and Janssen-related marketing and market access activities. Research and development expenses declined to $(96.0) million as patient dosing phases of major cilta-cel trials substantially concluded, partly offset by higher pipeline investment.

Net income was $33.2 million, compared with a net loss of $(125.4) million, reflecting improved operating performance and lower unrealized foreign currency exchange losses. Adjusted net income was $63.1 million, compared with adjusted net income of $10.1 million. Income tax expense rose to $(22.3) million as taxable income increased across U.S., Belgium and PRC entities. The unresolved advance pricing agreement with the Chinese Tax Authority remains important because the final tax outcome could differ materially from the amount reflected in the financial statements.

Liquidity was bolstered by the ADS offering, which generated net proceeds of approximately $212 million. Cash and cash equivalents and time deposits were approximately $965 million as of June 30, 2026. Quarterly operating cash flow was $(20.9) million and investing cash flow was $(120.0) million, while financing cash flow was $167.7 million. Management stated that this liquidity will provide runway beyond 2026 and that it expects company-wide profit, defined as Adjusted Net Income, in 2026.

Pipeline progress accompanied the commercial performance. LB2501 generated first clinical proof-of-concept, with 100% ORR (6/6) and 83.3% CR (5/6) at DL2 following a single infusion. LB2102 reported an ORR of 28.6% and DCR of 78.6% at higher dose levels. The key reported execution points are continued CARVYKTI expansion, conversion of sales into profitability, management of commercial spending and cash use, the Chinese tax matter, and durability of the early clinical data.

Management, verbatim

Our second quarter results demonstrate the strength of our commercial and innovation engines at Legend Biotech.

Alan Bash, Interim Chief Executive Officer of Legend Biotech

CARVYKTI continued to deliver growth as we expand patient access globally, including the most recent launch in Ireland, our 19 th market.

Alan Bash, Interim Chief Executive Officer of Legend Biotech

With meaningful commercial and clinical momentum and a strengthened balance sheet, we remain confident in our ability to advance innovation and progress toward company-wide profitability.

Alan Bash, Interim Chief Executive Officer of Legend Biotech

Not in the filing

stated, not guessed
  • Gross margin was not reported.
  • Free cash flow was not reported.
  • A tax rate was not reported.
  • Total operating expenses were not reported as a single line item.
  • Prior-quarter comparisons were not reported for the quarterly financial metrics.
  • Forward revenue guidance was not reported.
  • Forward gross-margin guidance was not reported.
  • Forward operating-expense guidance was not reported.
  • Forward tax-rate guidance was not reported.
  • Share repurchases, dividends, or other shareholder capital returns were not reported.
  • A total debt figure was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about LEGN earnings dates

When is Legend Biotech's next earnings date?
AlphAI has no date for LEGN yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.